|Bid||75.44 x 1000|
|Ask||75.50 x 900|
|Day's Range||74.42 - 75.89|
|52 Week Range||71.65 - 92.57|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||17.95|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||110.83|
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a general business update.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganesh Vedantham, as Senior Vice President, Technical Development filling two key strategic roles.